Merck Stock Surges as Investors Snap Up Unusually Large Options Bets
Merck & Co., Inc., a global healthcare company, has been the target of unusually large options trading activity. On Monday, investors purchased 227,658 call options on the stock, representing an increase of approximately 784% compared to the typical volume of 25,755 call options.
This surge in options trading comes as Merck's pharmaceutical portfolio continues to grow, with its products including Keytruda, Gardasil, and Januvia. The company's stock has a market cap of $357.30 billion and a price-to-earnings ratio of 115.86.
The unusual options activity may be a sign that investors are optimistic about Merck's future performance. In the second quarter, the company reported revenue of $16.61 billion, beating analysts' expectations of $16.37 billion.